close
read more
Our group
Governance
Global presence
Key figures
History
Vocation, vision and values
Culture
Financial Results
Servier Institute
Our healthcare offering
Servier medicines
Generic medicines
e-Health solutions
Our areas of expertise
Research & Development
Therapeutic areas
Development portfolio
Clinical trials
Regulatory affairs
Pharmacovigilance
Servier Paris-Saclay R&D Institute
Medical promotion
Industry
Industrial quality
Production
Supply Chain
CDMO Services
Medical Affairs
Third-Party Sponsor studies
Business development & licensing
Our commitments
Patient
Ethics & Compliance
Commitment to transparency
CSR approach
Fight against counterfeiting
Supplier relationship
Mécénat Servier Charity Fund
Newsroom
News
Press release
Insight
Corporate publishing
Medical publishing
FR
MEDIATOR INFORMATION
NEWS
ROOM
News
Press release
Insight
Corporate publishing
Medical publishing
Servier certified Top Employer Europe 2022!
20 / 01 / 2022
News
Servier presents its 2020/21 annual results, its R&D strategy and pipeline
18 / 01 / 2022
News
Pasteur-Weizmann/Servier Prize 2021: Prof. Catherine Lubetzki awarded for her work in the treatment of multiple sclerosis
09 / 12 / 2021
News
Immuno-oncology: Servier and Aqemia cooperate on AI and quantum physics-driven drug discovery
03 / 12 / 2021
News
Servier joins the Act4Nature International Initiative
01 / 12 / 2021
News
Servier invests 100 million euros in a new production unit at its Oril Industrie site
25 / 11 / 2021
News
Egis inaugurates two new plants in Körmend
19 / 11 / 2021
News
World Pancreatic Cancer Day: Servier strives to make progress in cancer treatments
18 / 11 / 2021
News
World Diabetes Day: promoting prevention, treatment, and care of diabetes
14 / 11 / 2021
News
Immuno-oncology: Servier and Pieris announce dosing of first patient in phase 1/2 trial
08 / 11 / 2021
News
World Mental Health Day: a public health priority
10 / 10 / 2021
News
Neurodegenerative diseases: Servier enter into a new research collaboration
07 / 10 / 2021
News
